Full Press Release Details
Medical Announces MedTech Industry Veteran Joe Mullings will Moderate the Next Access-Ability Live by MBOT' Webinar
of Proven Medical Device Entrepreneurs and Surgical Robotics Pioneers Will Share Their Personal Experiences of Taking Innovative New
Technologies from Development to Commercialization
on the Current and Future Endovascular Market will be Highlighted
will be Held on Tuesday, January 10, 2023, at 2:00pm ET (11am PT)
Mass., January 6, 2023 - Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY Robotic System, the first
single-use endovascular robotic system, announced that Joe Mullings, a renowned and successful leader in the medtech space, will moderate
the next Access-Ability Live by MBOT webinar. The webinar episode will be held on Tuesday, January 10, 2023, at 2:00pm
ET (11am PT), and will feature proven medical device entrepreneurs and recognized pioneers in the surgical robotics field.
Mullings is Chairman & CEO of The Mullings Group Companies, including TMG Search, Dragonfly Stories & TMG360 Media. The search
firm is responsible for more than 8,000 successful searches in the medtech / healthtech industry working with over 800 companies ranging
from multi-billion-dollar organizations to emerging tech startups. Dragonfly Stories is the media production company behind the 7x Telly
Award-Winning video docuseries, "TrueFuture", of which Joe is the host. Dragonfly specializes in generating attention &
awareness campaigns for companies globally.
Mullings, leveraging his vast knowledge and experience in the medtech space, will guide the panelists to highlight the unmet medical
needs in the endovascular space, specifically focusing on today's landscape and how new technologies and products being developed
today will reshape the endovascular procedure market in the future.
Access-Ability Live by MBOT webinar series focuses on key topics in the healthcare and endovascular space. Each month,
the Company will be partnering with industry leaders, such as physicians, hospital administrators, entrepreneurs, technicians and financial
experts for a live discussion and Q&A session to address top-of-mind topics related to endovascular procedures.
can register for the upcoming webinar here: https://us06web.zoom.us/webinar/register/WN_jtCpAT8_SC-cVMn2WBqpdw
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms
provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for
patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available
made in this press release or by members of Microbot's management team and others on Access-Ability Live, relating to future financial
and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical
Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the
Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such
as "will," "believes," "plans," "anticipates," "expects" and "estimates")
should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without
limitation, market conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY and
the One & Done technologies, the outcome of its studies to evaluate LIBERTY, the One & Done technologies and other
existing and future technologies, any failure or inability to recruit physicians and clinicians to serve as primary investigators to
conduct regulatory studies, which could adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical
trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain
future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found
under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update
these forward-looking statements, except as required by law.
views and opinions expressed by guests of the Access-Ability Live by MBOT webcast series are theirs solely, and do not necessarily reflect
the statements, views and opinions of their employers, organizations and/or associations, or of Microbot Medical Inc. and its subsidiaries.
Certain guests of Access-Ability are members of the Scientific Advisory Board (SAB) of Microbot or paid consultants of Microbot, and
have received compensation for their services to Microbot.